GCL
REVB icon

Glazer Capital LLC’s Revelation Biosciences REVB Stock Holding History

Glazer Capital LLC’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed -$4.07M – 847
2021
Q3 		$4.07M Buy
+2
New +$4.05M 0.07% 306

Other funds holding REVB

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Glazer Capital LLC's REVB Position: Q4 2021 in Review

Glazer Capital LLC sold out of Revelation Biosciences (REVB) in Q4 2021, closing a stake of 2 shares — an estimated $4.07M sold.

Glazer Capital LLC first reported a position in REVB in Q3 2021 and held it in 1 quarter. The position peaked at $4.07M in Q3 2021. 7 funds tracked by Wall St. Rank hold REVB as of Q4 2021.

  • Glazer Capital LLC reported no remaining Revelation Biosciences position as of Q4 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 2 Revelation Biosciences shares in Q4 2021, an estimated $4.07M.
  • Glazer Capital LLC first reported a position in Revelation Biosciences in Q3 2021 and held it in 1 quarter.
  • Glazer Capital LLC's Revelation Biosciences position peaked at $4.07M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Revelation Biosciences as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.